Jayesh Desai, Sophia Frentzas, Marwan Fakih, Malaka Ameratunga, Siobhan O'Neill, Meredith Pelster, Brian N. Stein, Amy Body, Bai Li, Ross M. Strauss, Yating Zhao, Gaohong Dong, Michael Cecchini. "First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.4_suppl.123